Effect of niacin on endothelial function: A systematic review and meta-analysis of randomized controlled trials

Vascular Medicine (United Kingdom)

Volumn 19, Issue 1, 2014, Pages 54-66

  Sahebkar, Amirhossein ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

coronary artery disease; dyslipidemia; endothelium; nicotinic acid; randomized controlled trial; vascular disease

Indexed keywords

CORONARY ARTERY DISEASE; DYSLIPIDEMIA; ENDOTHELIUM; NICOTINIC ACID; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE;

AGED; BRACHIAL ARTERY; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MIDDLE AGED; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATION;

EID: 84894451566     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X13515766     Document Type: Article

References (65)

1. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999 ; 31: 23-37
2. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 ; 109: III27-32
3. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated vasodilation in the brachial artery of patients with chest pain. Am J Cardiol. 2000 ; 86: 207-210
4. Gori T, Münzel T. Oxidative stress and endothelial dysfunction: therapeutic implications. Ann Med. 2011 ; 43: 259-272
5. Engler MM, Engler MB, Malloy MJ, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003 ; 108: 1059-1063
6. Zhang C. The role of inflammatory cytokines in endothelial dysfunction. Basic Res Cardiol. 2008 ; 103: 398-406
7. Van Boven AJ, Jukema JW, Paoletti R. Endothelial dysfunction and dyslipidemia: possible effects of lipid lowering and lipid modifying therapy. Pharmacol Res. 1994 ; 29: 261-272
8. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009 ; 120: 502-509
9. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 ; 376: 1670-1681
10. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012 ; 59: 1521-1528
11. Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008 ; 14: S3-28
12. Berrougui H, Momo CN, Khalil A. Health benefits of high-density lipoproteins in preventing cardiovascular diseases. J Clin Lipidol. 2012 ; 6: 524-533
13. Toikka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999 ; 147: 133-138
14. Digby JE, Ruparelia N, Choudhury RP. Niacin in cardiovascular disease: recent preclinical and clinical developments. Arterioscler Thromb Vasc Biol. 2012 ; 32: 582-588
15. Bregar U, Jug B, Keber I, Cevc M, Sebestjen M. Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. Heart Vessels. :
16. Philpott AC, Hubacek J, Sun YC, Hillard D, Anderson TJ. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. Atherosclerosis. 2013 ; 226: 453-458
17. Chow DC, Stein JH, Seto TB, et al. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS. 2010 ; 24: 1019-1023
18. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function. A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol. 2009 ; 54: 1787-1794
19. Warnholtz A, Wild P, Ostad MA, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis. 2009 ; 204: 216-221
20. Thoenes M, Oguchi A, Nagamia S, et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract. 2007 ; 61: 1942-1948
21. Benjó AM, Maranhão RC, Coimbra SR, et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: Effects of niacin treatment. Atherosclerosis. 2006 ; 187: 116-122
22. Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2007 ; 193: 361-365
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009 ; 339: b2535
24. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT Green S, ed. The Cochrane Collaboration ; 2009 :
25. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005 ; 20: 13
26. Sahebkar A. Does PPARγ(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis. DNA Cell Biol. 2013 ; 32: 188-198
27. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000 ; 56: 455-463
28. Borenstein M, Hedges L, Higgins J, Rothstein H Comprehensive Meta-analysis. Englewood NJ: Biostat ; 2005 :
29. De Jongh RT, Serné EH, Ijzerman RG, De Vries G, Stehouwer CDA. Free fatty acid levels modulate microvascular function: Relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes. 2004 ; 53: 2873-2882
30. See VY, DeNofrio D, Goldberg L, et al. Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. Am J Cardiol. 2003 ; 92: 11-15
31. Hamilton SJ, Chew GT, Davis TM, Watts GF. Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diab Vasc Dis Res. 2010 ; 7: 296-299
32. Tavintharan S, Woon K, Pek LT, et al. Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. Atherosclerosis. 2011 ; 215: 176-179
33. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006 ; 22: 2243-2250
34. Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag. 2007 ; 3: 159-164
35. Kuvin JT, Ramet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002 ; 144: 165-172
36. Andrews TC, Whitney EJ, Green G, Kalenian R, Personius BE. Effect of gemfibrozil ± niacin ± cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels < 160 mg/dl and high-density lipoprotein cholesterol levels < 40 mg/dl. Am J Cardiol. 1997 ; 80: 831-835
37. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010 ; 121: 110-122
38. Vaccari CS, Nagamia S, Thoenes M, Oguchi A, Hammoud R, Khan BV. Efficacy of controlled-release niacin in treatment of metabolic syndrome: Correlation to surrogate markers of atherosclerosis, vascular reactivity, and inflammation. J Clin Lipidol. 2007 ; 1: 605-613
39. Kurbanov RD, Shek AB, Tashkenbaeva NF. Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris. Ter Arkh. 2006 ; 78: 38-41
40. Wang Q, Liang X, Wang L, et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis. 2012 ; 221: 536-543
41. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation. 2003 ; 107: 2944-2948
42. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000 ; 41: 1481-1494
43. Li XA, Titlow WB, Jackson BA, et al. High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem. 2002 ; 277: 11,058-11,063
44. Uittenbogaard A, Shaul PW, Yuhanna IS, et al. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem. 2000 ; 275: 11,278-11,283
45. Seetharam D, Mineo C, Gormley AK, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006 ; 98: 63-72
46. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?. Prog Lipid Res. 2012 ; 51: 314-324
47. Lukasova M, Hanson J, Tunaru S, Offermanns S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol Sci. 2011 ; 32: 700-707
48. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010 ; 30: 968-975
49. Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am J Physiol Endocrinol Metab. 2009 ; 296: E549-558
50. Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol. 2003 ; 14: 561-566
51. Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009 ; 202: 68-75
52. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004 ; 164: 697-705
53. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol. 1998 ; 82: 74U - 81U
54. Zhang L, Gong D, Li S, Zhou X. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus. Atherosclerosis. 2012 ; 223: 78-85
55. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 ; 365: 2255-2267
56. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004 ; 15: 420-426
57. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). J Am Med Assoc. 2002 ; 288: 49-57
58. Ye Y, Li J, Yuan Z. Effect of antioxidant vitamin supplementation on cardiovascular outcomes: a meta-analysis of randomized controlled trials. PLoS One. 2013 ; 8: e56803
59. Clofibrate and niacin in coronary heart disease. JAMA. 1975 ; 231: 360-381
60. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004 ; 110: 3512-3517
61. Taylor A, Villines T, Stanek E, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009 ; 361: 2113-2122
62. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010 ; 55: 2721-2726
63. Brown B, Zhao X, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001 ; 345: 1583-1592
64. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013 ; 61: 440-446
65. Black MA, Cable NT, Thijssen DH, Green DJ. Impact of age, sex, and exercise on brachial artery flow-mediated dilatation. Am J Physiol Heart Circ Physiol. 2009 ; 297: H1109-1116